Mutant huntingtin impairs immune cell migration in Huntington disease

Journal of Clinical Investigation

Volumn 122, Issue 12, 2012, Pages 4737-4747

  Kwan, Wanda ^a,b   Träger, Ulrike ^b   Davalos, Dimitrios ^b   Chou, Austin ^a,b   Bouchard, Jill ^a,b   Andre, Ralph ^c   Miller, Aaron ^d,g   Weiss, Andreas ^e   Giorgini, Flaviano ^d,h   Cheah, Christine ^d   Möller, Thomas ^d   Stella, Nephi ^d   Akassoglou, Katerina ^a,b   Tabrizi, Sarah J ^c   Muchowski, Paul J ^a,b,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Taube Koret Center for Huntington's Disease Research   (United States)

^g Department of Pharmaceutical Sciences   (United States)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; HUNTINGTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; GENE DELETION; HUNTINGTON CHOREA; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MICROGLIA; MONOCYTE; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ACTIN DEPOLYMERIZING FACTORS; ACTINS; ADENOSINE TRIPHOSPHATE; ANIMALS; CELL SURFACE EXTENSIONS; CELLS, CULTURED; CHEMOTAXIS; COMPLEMENT C5A; HUMANS; HUNTINGTON DISEASE; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MONOCYTES; MUTATION; MYELOID CELLS; NERVE TISSUE PROTEINS; PERITONEUM; THIOGLYCOLATES; TIME-LAPSE IMAGING;

EID: 84870534288     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64484     Document Type: Article

References (74)

1. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A. Huntington's disease: the current state of research with peripheral tissues. Exp Neurol. 2009; 219(2):385-397.
2. van der Burg JM, Bjorkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009;8(8):765-774.
3. Hult S, et al. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab. 2011;13(4):428-439.
4. Bjorkqvist M, et al. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet. 2005;14(5):565-574. (Pubitemid 40309582)
5. Propert DN. Presymptomatic detection of Huntington's disease. Med J Aust. 1980;1(12):609-612. (Pubitemid 10011601)
6. Lodi R, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol. 2000;48(1):72-76. (Pubitemid 30432433)
7. Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RA. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology. 2008;71(19):1506-1513.
8. Moscovitch-Lopatin M, et al. Optimization of an HTRF assay for the detection of soluble mutant Huntingtin in human buffy coats: a potential biomarker in blood for Huntington disease. PLoS Curr. 2010;2:RRN1205.
9. Leblhuber F, et al. Activated immune system in patients with Huntington's disease. Clin Chem Lab Med. 1998;36(10):747-750. (Pubitemid 28521525)
10. Dalrymple A, et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007;6(7):2833-2840. (Pubitemid 47122377)
11. Bjorkqvist M, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med. 2008; 205(8):1869-1877.
12. Wild E, et al. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr. 2011; 3:RRN1231.
13. Anderson AN, Roncaroli F, Hodges A, Deprez M, Turkheimer FE. Chromosomal profiles of gene expression in Huntington's disease. Brain. 2008; 131(pt 2):381-388. (Pubitemid 351197616)
14. Borovecki F, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A. 2005; 102(31):11023-11028. (Pubitemid 41105986)
15. Runne H, et al. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci U S A. 2007; 104(36):14424-14429. (Pubitemid 350003277)
16. Kwan W, et al. Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci. 2012;32(1):133-142.
17. Sapp E, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 2001;60(2):161-172. (Pubitemid 32172419)
18. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985;44(6):559-577. (Pubitemid 16196286)
19. Simmons DA, Casale M, Alcon B, Pham N, Narayan N, Lynch G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia. 2007;55(10):1074-1084. (Pubitemid 47066747)
20. Lotharius J, et al. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci. 2005;25(27):6329- 6342. (Pubitemid 40962528)
21. Tai YF, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007;130(pt 7):1759-1766. (Pubitemid 47343790)
22. Tai YF, et al. Imaging microglial activation in Huntington's disease. Brain Res Bull. 2007;72(2-3):148-151. (Pubitemid 46389550)
23. Politis M, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp. 2011;32(2):258-270.
24. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6(12):1182-1190. (Pubitemid 43045626)
25. Madri JA, Graesser D. Cell migration in the immune system: the evolving inter-related roles of adhesion molecules and proteinases. Dev Immunol. 2000;7(2-4):103-116.
26. Stossel TP. On the crawling of animal cells. Science. 1993;260(5111):1086-1094. (Pubitemid 23186781)
27. Jones GE. Cellular signaling in macrophage migration and chemotaxis. J Leukoc Biol. 2000;68(5):593-602.
28. Inoue K. Microglial activation by purines and pyrimidines. Glia. 2002;40(2):156-163. (Pubitemid 35337373)
29. Koizumi S, et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature. 2007; 446(7139):1091-1095. (Pubitemid 46676051)
30. Davalos D, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8(6):752-758. (Pubitemid 43085841)
31. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005; 308(5726):1314-1318. (Pubitemid 40746128)
32. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci. 2009; 29(13):3974-3980.
33. Kurihara T, Warr G, Loy J, Bravo R. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med. 1997;186(10):1757-1762. (Pubitemid 27506288)
34. Blundell MP, Worth A, Bouma G, Thrasher AJ. The Wiskott-Aldrich syndrome: the actin cytoskeleton and immune cell function. Dis Markers. 2010; 29(3-4):157-175.
35. Slow EJ, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12(13):1555-1567. (Pubitemid 36857303)
36. Gray M, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28(24):6182-6195.
37. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol. 1990;27(2-3):229-237. (Pubitemid 20146292)
38. Haynes SE, et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci. 2006;9(12):1512-1519. (Pubitemid 44862659)
39. Irino Y, Nakamura Y, Inoue K, Kohsaka S, Ohsawa K. Akt activation is involved in P2Y12 receptor-mediated chemotaxis of microglia. J Neurosci Res. 2008;86(7):1511-1519. (Pubitemid 351642444)
40. Miller AM, Stella N. Microglial cell migration stimulated by ATP and C5a involve distinct molecular mechanisms: quantification of migration by a novel near-infrared method. Glia. 2009;57(8):875-883.
41. McKercher SR, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 1996;15(20):5647-5658. (Pubitemid 26385624)
42. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature. 2010;468(7321):253-262.
43. Ginhoux F, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841-845.
44. Boillee S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389-1392. (Pubitemid 43839552)
45. Ohsawa K, Imai Y, Kanazawa H, Sasaki Y, Kohsaka S. Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. J Cell Sci. 2000;113(pt 17):3073-3084.
46. Imai Y, Kohsaka S. Intracellular signaling in M-CSF-induced microglia activation: role of Iba1. Glia. 2002;40(2):164-174. (Pubitemid 35337374)
47. Dawe HR, Minamide LS, Bamburg JR, Cramer LP. ADF/cofilin controls cell polarity during fibroblast migration. Curr Biol. 2003;13(3):252-257. (Pubitemid 36178305)
48. Wang Y, Shibasaki F, Mizuno K. Calcium signal-induced cofilin dephosphorylation is mediated by Slingshot via calcineurin. J Biol Chem. 2005; 280(13):12683-12689.
49. Munsie L, et al. Mutant Huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. Hum Mol Genet. 2011;20(10):1937-1951.
50. Ma L, Morton AJ, Nicholson LF. Microglia density decreases with age in a mouse model of Huntington's disease. Glia. 2003;43(3):274-280. (Pubitemid 37047683)
51. Lynch G, et al. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J Neurosci. 2007; 27(16):4424-4434. (Pubitemid 46640726)
52. Reis SA, et al. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis. Hum Mol Genet. 2011;20(12):2344-2355.
53. Myre MA, Lumsden AL, Thompson MN, Wasco W, Macdonald ME, Gusella JF. Deficiency of huntingtin has pleiotropic effects in the social amoeba Dictyostelium discoideum. PLoS Genet. 2011; 7(4):e1002052.
54. Pascual O, Ben Achour S, Rostaing P, Triller A, Bessis A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc Natl Acad Sci U S A. 2011;109(4):E197-E205.
55. Cardona AE, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9(7):917-924. (Pubitemid 43980506)
56. Zwilling D, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011;145(6):863-874.
57. Goodman JC, Van M, Gopinath SP, Robertson CS. Pro-inflammatory and pro-apoptotic elements of the neuroinflammatory response are activated in traumatic brain injury. Acta Neurochir Suppl. 2008; 102:437-439.
58. Chaparro-Huerta V, Rivera-Cervantes MC, Flores- Soto ME, Gomez-Pinedo U, Beas-Zarate C. Proinflammatory cytokines and apoptosis following glutamate-induced excitotoxicity mediated by p38 MAPK in the hippocampus of neonatal rats. J Neuroimmunol. 2005;165(1-2):53-62. (Pubitemid 40984623)
59. Rogers JT, et al. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J Neurosci. 2011;31(45):16241-16250.
60. Rampersad RR, et al. Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS One. 2011;6(10):e25833.
61. Ishida Y, Gao JL, Murphy PM. Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J Immunol. 2008;180(1):569-579.
62. Boring L, et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest. 1997; 100(10):2552-2561. (Pubitemid 27514895)
63. Christensen PJ, et al. Expression and functional implications of CCR2 expression on murine alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2004;286(1):L68-L72. (Pubitemid 38055859)
64. Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS. Conditions associated with Huntington's disease at death. A case-control study. Arch Neurol. 1988; 45(8):878-880.
65. Herring AC, Koh WS, Kaminski NE. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem Pharmacol. 1998;55(7):1013-1023. (Pubitemid 28167723)
66. Ehrhart J, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation. 2005;2:29.
67. Mukhopadhyay S, et al. Lipopolysaccharide and cyclic AMP regulation of CB(2) cannabinoid receptor levels in rat brain and mouse RAW 264.7 macrophages. J Neuroimmunol. 2006;181(1-2):82-92. (Pubitemid 44827292)
68. Palazuelos J, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain. 2009;132(pt 11):3152-3164.
69. Bouchar J, et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci. In press.
70. Etzioni A, et al. Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med. 1992;327(25):1789-1792.
71. Jung S, et al. Analysis of fractalkine receptor CX(3) CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20(11):4106-4114. (Pubitemid 30314508)
72. Balcaitis S, Weinstein JR, Li S, Chamberlain JS, Moller T. Lentiviral transduction of microglial cells. Glia. 2005;50(1):48-55. (Pubitemid 40516819)
73. Saederup N, et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One. 2010;5(10):e13693.
74. Benn CL, Fox H, Bates GP. Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. Mol Neurodegener. 2008;3:17.